This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Tahini's === Tahini's is a fast-casual Mediterranean and Middle Eastern fusion restaurant chain founded in London, Ontario, in 2012 by Omar Hamam. The chain is known for blending traditional shawarma with international cuisine, featuring items such as butter chicken shawarma, Jamaican jerk shawarma, and shawarma ramen. As of 2026, Tahini's operates over 70 locations across Canada and has begun expanding into international markets including the United States.
== Constitutional issues == Several of the convention's provisions are prefaced with the words, "Subject to its constitutional principles and the basic concepts of its legal system, each Party shall ..." According to Fazey, "This has been used by the USA not to implement part of article 3 of the 1988 Convention." Similarly, if a national prohibition on drug possession violated a nation's constitution, those provisions would not be binding on that country.
The external genitalia of a woman are collectively known as the vulva. This comprises the labia majora (outer labia), the labia minora (inner labia), the clitoris, the urinary meatus, and the vaginal opening. The labia majora extend from the mons pubis to the perineum. The size, shape, and color of the inner labia vary greatly. One is usually larger than the other. They may be hidden by the outer labia, or may be visible, and may become larger with sexual arousal, sometimes two to three times their usual diameter. The size of the labia can change because of childbirth. Genital piercings can increase labial size and asymmetry, because of the weight of the ornaments. In the course of treating identical twin sisters, S.P. Davison et al reported that the labia were the same size in each woman, which indicated genetic determination. In or around 2004, researchers from the Department of Gynaeology, Elizabeth Garret Anderson Hospital, London, measured the labia of 50 women between the ages of 18 and 50, with a mean age of 35.6:
Sources: en.wikipedia.org
=== Sponsorships === In the early 1990s, as part of PepsiCo's sponsorship of The NewsHour with Jim Lehrer (and its former moniker, The MacNeil/Lehrer NewsHour), Pizza Hut was included in the acknowledgment alongside Taco Bell and KFC, which PepsiCo owned at the time. In 2000, Pizza Hut was a part-time sponsor of Galaxy Motorsports' #75 Ford in the then NASCAR Cup Series, driven by Wally Dallenbach Jr. Pizza Hut was the shirt sponsor of English football club Fulham F.C. for the 2001–02 season. Terry Labonte drove selected events with Pizza Hut as the primary sponsor of his #44 car for Hendrick Motorsports in 2005. Brian Vickers also drove a Pizza Hut car in the NASCAR Busch Series for Hendrick. Pizza Hut purchased the naming rights to Major League Soccer club FC Dallas' stadium, Pizza Hut Park, prior to its opening in 2005, which were allowed to expire in January 2012. In October 2015, Pizza Hut signed sponsorship deals with the Dallas Mavericks, Dallas Stars, and American Airlines Center. In February 2018, Pizza Hut signed a sponsorship deal to be the official pizza sponsor for the National Football League. Pizza Hut sponsored the #14 Brad Jones Racing Holden ZB Commodore driven by Todd Hazelwood for both of the Darwin Triple Crown and Townsville 500 in 2021. In March 2022, Pizza Hut signed a sponsorship deal to be the official Quick Service Restaurant for the Supercars Championship.
== Experimental techniques == Since the original experiments by Geoffrey Harris investigating the communication of the hypothalamus with the pituitary gland, much has been learned about the mechanistic details of this interaction. Various experimental techniques have been employed. Early experiments relied heavily on the electrophysiology techniques used by Hodgkin and Huxley. Recent approaches have incorporated various mathematical models to understand previously identified mechanisms and predict systemic response and adaptation under various circumstances.
=== Environmental impact === On an industry level, supplementing one million cows with rBST would result in the same amount of milk produced while needing 157,000 fewer cows. Farmers are, therefore, able to improve milk production with a smaller dairy population. Some studies show that rBST-treated cows reduce the greenhouse gas footprint in comparison with conventional and organic dairy operations. Cady's study showed that excretion of nitrogen and phosphorus, two major environmental pollutants arising from animal agriculture, was reduced by 9.1 and 11.8%, respectively. Carbon dioxide is recognized to be the most important anthropogenic greenhouse gas, and livestock metabolism and fossil fuel consumption are the main sources of emissions from animal agriculture.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.